Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase I/Ib Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and With Checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma

Summary

The purpose of this phase I/Ib study is to evaluate the safety and feasibility of the pressure-enabled intrapancreatic infusion of SD-101 alone or in combination with intravenous checkpoint blockade in patients with locally advanced pancreatic cancer.

General Information

NCT#: NCT05607953
Study ID: TS-PERIO-03
Trial Phase: Phase I

Trial Sponsor: TriSalus Life Sciences
Therapies Used in This Trial: Pembrolizumab, SD-101

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search